HIV invades the central nervous system very early on in infection, according to Shibani Mukerji, MD, PhD, of the Department of Neurology at Massachussetts General Hospital.
“Within days of plasma viremia, HIV RNA can be detected in the cerebrospinal fluid [CSF], and this early penetration is hypothesized to set the stage for future neurocognitive impairment,” Mukerji said during a presentation at IDWeek 2017 in San Diego, CA.
The central nervous system (CNS) has its own unique immune surveillance, Mukerji explained, but recent studies indicate that this immune surveillance is complimented by input from the peripheral immune system. Peripheral cells, including t-lymphocytes, enter the CNS under normal conditions, but during HIV infection and immune activation, there is a heightened trafficking of these cells, which can harbor HIV.
“When an HIV infected cell enters the brain, there is a release of inflammatory cytokines and chemokines, which then attract more immune cells. There is a cycle of inflammation that is established,” Mukerji said.
Both in vivo and in vitro studies suggest that these inflammatory processes, and perhaps toxic effects from viral proteins, will eventually damage neurons, driving brain atrophy and neurocognitive impairment. According to Mukerji, this neurocognitive decline is not due to direct viral infection, but bystandards for these local inflammatory processes.
In primary HIV infection, CSF inflammatory markers are elevated, which Mukerji explained correlate with systematically low CD4 cell counts, which has been associated with worse neurocognitive outcomes, even when excluding opportunistic infections.
Mukerji pointed to a recent study at UCSF to illustrate this point. In the study, researchers monitored the first 20 days of estimated exposure to HIV, and identified that there is already increased activated CDAT cells present in the CSF at the time of peak viremia, and that this is carried over into chronic HIV.
“What’s slightly concerning to me is that in this acute phase, we are already seeing differences in brain volume and structural brain MRI,” Mukerji said.
The MRI study calculated the volume of a brain tissue, and showed is that within a very small number of days after estimated infection, and prior to antiretroviral initiation, volumes were getting smaller.
“What this really suggests is that within weeks of estimated infection, HIV may already be altering the underlying neural anatomy of our brains and altering our neural networks,” Mukerji said.
While HIV may play a role in exacerbating neurocognitive impairment, similarly, neurocognitive impairment can result in poorer HIV outcomes.
“Neurocognitive disorders affect antiretroviral adherence and viremia, and can affect work, financial considerations, and impact overall quality of life,” Mukerji said.
20% of new HIV diagnoses in 2015 were in people over the age of 50, and 40% of those individuals had late-stage infection at the time of their diagnosis. Odds of neurocognitive impairment increased with 20% with every decade of life.
Earlier diagnosis is key to treating these patients both to achieve better HIV and neurocognitive outcomes. However, despite ART, it is known that neuroinflammation is established in acute HIV infection that persists into chronic infection.
“There is decrease in some, but not all CSF cytokine markers [with earlier ART initiation], and interestingly they did show that viral diversity in the CSF increased the longer it took to start ART,” Mukerji said. “We’re getting new data suggesting that maybe earlier treatment for ART may improve some cognitive markers, but I think that needs to be tested out a little bit more.”